Hypertrophic Obstructive Cardiomyopathy Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
Condition: HOCM, Hypertrophic Obstructive Cardiomyopathy Interventions: Drug: Mavacamten; Drug: Placebo Sponsor: MyoKardia, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2020 Category: Research Source Type: clinical trials
